From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV
In highly treatment-experienced PLWH harbouring MDR strains, who were virologically suppressed, switching to BIC/FTC/TAF was well tolerated with maintenance of virological control.
Authors
- Pilar Vizcarra (ORCID: https://orcid.org/0000-0001-8553-6995)
- Alejandro Vallejo (ORCID: https://orcid.org/0000-0001-5360-878X)
- Ana Hernández Moreno (ORCID: https://orcid.org/0000-0002-4407-3864)
- José L. Casado (ORCID: https://orcid.org/0000-0002-7639-8591)
- José L Blanco
- Isabel Izuzquiza
Institutions
- Instituto Cajal (ES)
- Hospital Clínic de Barcelona (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Medical Research Network (US)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1093/jac/dkaf357
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40